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Abstract 
There are different factors that affect drug interaction. This interaction may be Pharmacokinetic or 
Pharmacodynamic. Either case can lead to decrease in efficacy or increase in toxicity of the drugs but, our 
concern in this paper is on the half-life of a drug. Here, we are looking at the half-life concentration of drugs 
taking anti-depressant drugs as a case study (Setraline and Tranylcypomine). In terms of half-life of a particular 
drug, it was shown that drugs with short half-lives are less susceptible to interaction than drugs with long half-
lives. This fact is used to establish that in the administration of drugs to a patient (since patients receive at least 
10 to 20 drugs at a goal), the half- life needs to be considered. 
Keywords: Drug, Pharmacokinetics, Pharmacodynamics and Half-Life. 
 
1. Introduction 
The interaction of a drug can be synergistic (when the drugs effect is increased) or antagonistic (when the drugs 
effect is decreased) or a new effect can be produced on its own. Typically, interactions between drugs come to 
mind (drug-drug interactions). However, interactions may also exist between drugs and foods (drug-food 
interactions), as well as drug and medicinal plants or herbs (drug-plant interactions). People taking 
antidepressant drugs such as monoamine oxidase inhibitors should not take food containing tyramine as 
hypertensive crisis may occur (an example of a drug-food interaction). These interactions may occur out of 
accidental misuse or due to lack of knowledge about the active ingredients involved in the relevant substance, 
10 . To initiate a desired drug action is a qualitative choice, but when the qualitative choice is made, 
considerations of quantity immediately arise. When a Physician prescribes a drug and the patient takes it, their 
main concern is with the effect on the patient disease. To obtain the right effect at the right time, for the right 
duration and with minimum risk of unpleasantness or harm is what Pharmacokinetics is all about. 
Pharmacokinetics is the study of the time course of drug and metabolite levels in different fluids, tissue and 
excreta of the body and the Mathematical relationships to develop models to interpret such data. 4. 
The effect of a drug depends most fundamentally on how much the drug is taken. Drugs are taken through 
various routes as the case may differ. Drug administration route can strongly influence the effects that drug has 
7. These routes are oral, injection, inhalation, intranasal, sublingual and transdermal. 
 
2. Half-Life 
The manner, in which plasma drug concentration rises or falls when dosing has begun, altered or ceased follows 
certain simple rules which provide a means for rational control of drug effect. 7. Central to understanding these, 
is the concept of half-life denoted by 	


. This is the time in hours or in days necessary for the concentration of 
drug in the plasma to decrease to one half, 4. 
 
3. Methodology 
The stochastic Ito process representing concentration in one- compartment pharmacokinetics model with 
unanticipated drug interactions drug interactions can be expressed as follows: 

  = − +  +  − 1                                                                                        (1) 
Where K is the elimination rate constant or the trend rate constant in the absence of drug interactions;  is the 
variance rate in the absence of the interaction-inducing agent; d is differential time and dz is the differential of z, 
the Wiener variable; and the Poisson jump variable, d, takes a value of 1 if the jump occurs (the probability of 
this is characterized by , where  is the occurrence rate of interaction events, and t is time) and a value zero if a 
jump does not occur. The –  term characterizes the Pharmaconetic trend; the   term characterizes the 
uncertainty caused by “usual garden-variety” variability or white noise, and (Y−1  represents the increased 
variability caused by the sudden unanticipated arrival of the interaction. Upon the occurrence of an interaction, 
the elimination rate constant “jump” instantaneously by (Y−1, causing the concentration to increase from C to 
CY. Thus, the right-hand side of eqn. 1 is a stochastically modified elimination rate constant that contains a 
Gaussian-distributed white-noise (  ) and a poisson-distributed noise term [(  − 1 )   ] caused by the 
interaction. 
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3.1. Pharmacodynamic Model  
 If the effect is a twice-differential function of only concentration and time, the stochastic process for effect is 
also similar, and can be written as follows: 

 = − +  +  − 1                                                                 (2) 
In eqn.( 2), the subscript E refers to effect. However, an extended version of Ito’s lemma can be used to derive 
the values for the drift rate and variance rate in terms of the pharmacokinetic parameters and pharmacodynamic 
effect equation.    
 = −     


 
 − !    +   " #                                                                           (3) 
 =  !   #                                                                                                                                 (4) 
 = $ %                                                                                                                                                             (5) 
The commonly used simple and sigmoid $&'(  models are twice- differentiable functions of concentration alone, 
and the time partial derivative of effect with respect to time is zero, which allows the simplification of eqn.( 3) to: 
 = −   !  


 
 − !   #                                                                                                                             (6) 
In the simple $&'(   model, mean jump values in effect are likely to be more prominent with drugs that are used 
in the linear effect range, because        will be larger. At saturation, the jumps in concentration will not result in 
jumps in effect. 
4. Effect of Interaction on Drug Concentration.  
 When the percentage change in drug concentration caused by the interaction-inducing agent is log-normally 
distributed, i.e., the jumps ) are random variables drawn from a log-normal distribution with mean (*  and 
variance (+, the ratio ! !,-       also is log normally distributed. However, the variance parameter is Poisson 
distributed. 
Additionally, because the mean *  is the expectation ∈ /0 + 1
 = * + 1


                                                       (7) 
Surprisingly, despite the discontinuous nature of the underlying stochastic processes, the distribution of 
concentrations is continuous. Press first provided analytical expressions for the probability density function of In 
C(t) but did not assume a deterministic trend. However, 2 extended the Press equation to accommodate a 
deterministic trend. With these assumptions, the probability density function for concentration is stationary over 
time and is given by: 
In 
"
3  ⇒ ∑
6789:";
<!
∞<>,  N− + 0*,  + 0+                                                                                              (8) 
The symbol   should be read as “ is distributed as “ and the N− + 0*,  + 0+ is the probability 
density function of a normal distribution with mean , − + 0* and variance  + 0+. 
The distribution in eqn. 8 is a process that consists of Poisson events superimposed on events following another 
independent distribution that, in this case, happens to be log-normal. With the method of characteristic functions, 
the various moments of this distribution can be calculated (Press, 1967). The moments can be used to 
demonstrate that this distribution is leptokurtic. By definition, leptokurtosis implies that the distribution has a 
fatter tail than a comparable normal distribution, i.e., the probability of observing outlying high-concentration 
events is much greater than that for a normal distribution. Additionally, the skewness of the distribution is 
determined by *, i.e., if * is negative, the distribution has negative skewness; if * is zero, the distribution is 
symmetric. The second moment or variance of the distribution in the presence of interactions is given by the 
following: 
Variance =  + * + +                                                                                                                         (9) 
The variance relationship (eqn.9) demonstrate that the variance in the presence of interactions is increased and 
that both the magnitude (* and variability ()of the interaction are important. 
More frequently, side effects from interaction-inducing agents are caused by drug concentrations exceeding the 
minimum toxic dose. To determine the probability P In C > /0 !" of concentrations exceeding the minimum 
toxic dose, !", the cumulative probability distribution function has to be calculated from eqn. 8 as follows: 
P In C > /0 !" = C ∑ 6789:";<!∞<>,  N− + 0*,  + 0+E(>∞(>F<9  
However, in eqn.9 only the terms containing the normal distribution are functions of concentration and 
P In C > /0 !" = ∑ 6789:";<!∞<>, 1 − C ∑ 6
789:";
<!
∞<>,  N− + 0*,  + 0+E(>∞(>F<9 # 
Or alternatively, 
P In C > /0 !" = ∑ 6789:";<!∞<>, 1 − ф− + 0*,  + 0+                                                             (11) 
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In eqn. (11),   ф− + 0*,  + 0+  is the cumulative probability distribution function of the normal 
distribution with mean − + 0* and variance  + 0+ evaluated at In !" . 
In the limit of small values of , Poisson process can be approximated by a Bernoulli process1. The Bernoulli 
process is a model for interaction processes such that over a period of time, either no interaction or just one 
interaction occurs. The cumulative probability density function for a Bernoulli mixture of Gaussians is as 
follows: 
P In C > /0 !" =1 −  ф−,  +  ф− + *,  + +                                                               (12) 
Thus, both models allow for discontinuous jumps but result in continuous distribution functions. In the following 
sections, eqn. (12) is used because it is reasonable to assume that drug interactions are likely to be relatively rare 
events with small values of . 
 
5. Results and Analysis 
1000ml conical flask, 25ml beaker, 10ml and 1ml pipette, 12 large test tubes, water tank, drugs(sertraline- 
50mg/ml and tranylcypromine -75mg/ml) both drugs are anti-depressants drugs. 
1. The concentration level for Sertraline can been seen in the table below: 
Tube Mg/ml Conc. H10I 
A 5 50,000 
B 0.5   5,000 
C 0.25   2,500 
D 0.125   1,250 
E 0.0625      625 
F 0.03125      313 
G 0.01562      156 
H 0.0078125        78 
I 0.0039063        39 
J 0.0019531        20 
K 0.0009766         10 
L 0.0004883           5 
 
CALCULATIONS: 
Using !J = !J 
1K"  Dilution,     ! =  	L	L
   = 50mg/ml ×1ml ÷ 10ml = 5mg/ml 2< Dilution,    5mg/ml×1ml ÷ 10ml =0.5mg/ml 
 
12"M Dilution 0.0009766× 1ml ÷ 10ml = 0.0004883mg/ml 
For Sertraline: 
TUBE TIME (hr) CONC. (Mg/ml) CONC. (Mg/ml x 10I   
 
Log of conc. (Mg/ml x10I  
A 1 0.03125 312.5 2.49 
B 2 0.03125 312.5 2.49 
C 3 0.02344 234.4 2.37 
D 4 0.01172 117.2 2.07 
E 5 0.005859 58.59 1.77 
F 6 0.002930 29.30 1.47 
G 7 0.001965 19.65 1.30 
H 8 0.001965 19.65 1.30 
I 9 0.0009825   9.83 1.0 
J 10 0.0009825   9.83 1.0 
K 11 0.00049125   4.90 0.69 
L 12 0.00049125   4.90 0.69 
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Tube Mg/ml Conc. H10I 
A 7.5 75000 
B 0.75    7500 
C 0.375      375 
D 0.1875      188 
E 0.09375      469 
F 0.04688      469 
G 0.02343      234 
H 0.01172      117 
I 0.00586        59 
J 0.00293        29 
K 0.00146        15 
L 0.00073        73 
 
CALCULATIONS: 
Using !J = !J 
1K" Dilution,     ! =  	L	L
   = 75mg/ml ×1ml ÷ 10ml = 7.5mg/ml 2< Dilution,    7.5mg/ml×1ml ÷ 10ml =0.75mg/ml 
. 
12"M Dilution 0.00146× 1ml ÷ 10ml = 0.00073mg/ml 
For Tranylcypromine: 
 
Tube Time (hr) CONC. (Mg/ml) CONC. (Mg/ml x10I  Log of conc. (Mg/ml x10I  
A 1 0.4688 4688 3.6 
B 2 0.4688 4688 3.6 
C 3 0.0352   352 2.5 
D 4 0.0176   176 2.2 
E 5 0.0088     88 1.9 
F 6 0.0044     44 1.6 
G 7 0.0022     22 1.3 
H 8 0.0022     22 1.3 
I 9 0.0011     11 1.0 
J 10 0.0011     11 1.0 
K 11 0.0001       1 0 
L 12 0.0001       1 0 
 
5.1. Confirmatory Test 
We applied student t-test to confirm that drugs with shorter half-lives are less susceptible to interaction than 
drugs with longer half-lives. 
NO: There is no significant difference between the means of the drugs. From the table above, we evaluate HPQQQQ = 
0.0842, JRSP = 0.029675,  HKQQQ = 0.00944 and JRSK = 0.001543219. We compared if the variances are assumed to 
be equal, using the variance ratio test. 
 T = JRSP  JRSK  =
0.029675
0.001543219 = 19.229 
At Y = 0.05,   T = 2.82 and since 19.229 > 2.82, the variances are assumed to be equal and as such we can 
evaluate the common variance. The calculated common variance [ = 0. 01541. 
Applying the student t-test as given below, we have 
 
 =  HPQQQQ −  H\QQQ
] <^ +

<_
_
= 0.0842 − 0.00944
0.01541]  + 
= 11.8 
 − `Rabc R Y = 0.05 dSef  Rgac[ ScR R 22 chScc[ ed dSccef i[ 2.07.  
It implies that, there is significant difference between the means of drugs. So, we reject ourNO and conclude that 
drugs with shorter half-lives are less susceptible to drug interaction than drugs with longer half-lives. 
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6. Recommendation 
When administering drugs to a patient, it is advisable to take into cognisance the half life of the drug. 
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